Persistent bronchodilatation induced by regular agonist administration may allow an Background -Regular, inhaled 2 agonists may increase airway responsiveness in increased allergen load to reach the airways. 4 Alternatively, tachyphylaxis of receptors presasthmatic subjects. The mechanism is not known but may be via an increase in airway ent on mast cells may reduce their stabilising effect and allow inflammatory mediator release inflammation. A study was undertaken to examine the effect of regular inhaled sal-in response to a lesser stimulus than is normally required.
lenge and allergen skin prick testing were per-   Spirometric tests were performed on a Vitaloformed. Subjects were eligible for inclusion in the study if they had a baseline FEV 1 of more graph dry spirometer (Vitalograph Co, Buckingham, UK). Each measurement was repeated than 80% of the predicted value and a maximal response plateau to methacholine of [15% until two curves were obtained in which the FEV 1 and forced vital capacity (FVC) were fall in FEV 1 . Written informed consent was obtained from all subjects and the study was reproducible to within 100 ml and the higher of these two values was recorded. approved by the ethics committee of the Central Sydney Area Health Service.
Sample sizes were calculated to give the study 80% power at the 5% significance level to detect a difference between treatment groups     in the change in the maximal response plateau Methacholine chloride (ACIC Inc, Ontario, to methacholine of 10% fall in FEV 1 . A previous Canada) was administered using a DeVilbiss study in this laboratory had shown that the No. 646 nebuliser (DeVilbiss Co, Somerset, within subject repeatability of the maximal re-Pennsylvania, USA) regulated by a breath acsponse plateau was 8.7% fall in FEV 1 .
tivated dosimeter (Rosenthal French, Baltimore, Maryland, USA) and attached to compressed oxygen at 138 kPa pressure. The dosimeter was set to allow nebulisation for 0.6   Eligible subjects were entered into a ran-seconds per inhalation which produced a mean (SE) output of 0.01 (0.0011) ml per inhalation. domised, double blind, placebo controlled, parallel trial of eight weeks duration. Participants A control dose of 0.9% sterile saline was administered at the commencement of each chalundertook a run in period of at least two weeks duration to establish the repeatability of the lenge, followed by methacholine chloride in concentrations of 3, 6, 25, 50, 100 and 200 mg/ methacholine response. At the end of the run in period a high dose methacholine challenge ml. Five inhalations, from slightly below functional residual capacity to total lung capacity, and a hypertonic saline challenge were performed on consecutive days. Induced sputum were taken of each solution. An additional five inhalations were taken of the 6 mg/ml solution samples were collected for sputum cytological testing during the hypertonic saline challenge. and an additional 10 inhalations were taken of the 200 mg/ml solution. This method delivered This was followed by a four week treatment period during which subjects took either 200 g methacholine chloride in cumulative, approximately doubling, doses ranging from salbutamol or matched placebo by metered dose inhaler, without a spacer device, four times 0.15 mol to 199 mol.
The FEV 1 was measured 60 seconds after daily (eight puffs/day). Subjects were tutored in the use of a metered dose inhaler and the the final inhalation of each solution. FVC was recorded at baseline, after the control dose, adequacy of their technique was checked before and after treatment. Upon completion of the when a 20% reduction in FEV 1 occurred, and after administration of the final dose. The protreatment period high dose methacholine and hypertonic saline challenges were repeated and cedure was terminated when a plateau had been established, when the highest dose had sputum samples were again collected. The trial concluded with a two week washout period at been administered, or when the FEV 1 had fallen by 60% of the control FEV 1 value. Inhaled the end of which a final high dose methacholine challenge was performed. At each assessment salbutamol, 200 g, was administered upon completion of the procedure. Subjects were visit subjects were asked to complete a questionnaire to document respiratory and nasal required to cease salbutamol or placebo treatment at least six hours before methacholine symptoms. Each canister of aerosol (salbutamol or placebo) was weighed before and after the challenge. treatment period to assess compliance. All challenge tests were performed by one investigator (DWE) at approximately the same time of day (±2 hours) for each subject.
   Challenges with hypertonic saline were undertaken on the day following methacholine challenge. A solution of 4.5% saline (Ajax    Atopic status was assessed by skin prick test Chemicals, Sydney, Australia) was administered via an Ultraneb 2000 ultrasonic reactions to 14 common aeroallergens. 12 Histamine and glycerol were used as positive and nebuliser (DeVilbiss Co, Somerset, Pennsylvania, USA) for durations of 30 seconds, negative controls, respectively. After 15 minutes the weal size was recorded as the long axis one minute, two minutes, four minutes, and two periods of eight minutes. 8 The canister and its perpendicular and the mean value was used in analyses. A reaction was regarded as containing the saline solution was weighed before and after the challenge, and the rate of positive if the weal size was 4 mm or greater. Subjects were considered atopic if they had a output of the nebuliser in ml/min was determined. The test was stopped when the FEV 1 positive reaction to any of the allergens tested. No subject had taken antihistamine med-fell by 20% from the baseline value or when the longest hypertonic saline exposure was ications during the three days prior to skin prick testing.
completed.
group.bmj.com on June 15, 2017 -Published by http://thorax.bmj.com/ Downloaded from   FEV 1 value against the log dose of methacholine or hypertonic saline. A maximal reSputum was induced during the hypertonic saline challenge. Subjects were asked to pro-sponse plateau to methacholine was established when the decrease in FEV 1 between two or duce sputum by forced coughing after the four and eight minute periods of inhaling hypertonic more of the final doses was less than 5% of the control FEV 1 value 13 and the level of the plateau saline. In subjects who failed to produce sputum during the standard challenge an ad-was defined as the mean of the fall in FEV 1 at these doses. By this definition of the plateau the ditional eight minute period of inhaled 4.5% saline was given after administration of 200 g maximal percentage fall in FEV 1 to hypertonic saline was also calculated. Dose response ratios of inhaled salbutamol.
(DRRs) to methacholine and to hypertonic saline were calculated from the first point of the plateau as the percentage fall in FEV 1 di-   At least four sputum plugs were selected from vided by the cumulative dose of methacholine or hypertonic saline.
14 the sputum samples from each subject; the plugs were smeared onto glass slides and alThe maximal response plateau to methacholine, FEV 1 , FVC, cytological, and ECP data lowed to air dry. When possible, plugs were selected from sputum produced late in the are reported as arithmetic means with 95% confidence intervals (95% CI); dose response procedure. All samples were smeared within two hours of production. Two slides from each ratios to methacholine are reported as geometric means with 95% CIs and the change in subject were fixed in absolute methanol for 10 minutes, then stained in undiluted May-DRR is reported in doubling dose units.
14 Two tailed paired t tests were used to analyse changes Grü nwald stain for 10 minutes, briefly rinsed in tap water, and counterstained in Giemsa within a treatment group for these data, and two tailed unpaired t tests were used to analyse stain diluted 1:10 in Giemsa buffer (pH 6.8). Two slides were also fixed in Carnoy's solution changes between the two treatment groups.
Maximal falls in FEV 1 and DRR to hypertonic for 10 minutes, dehydrated in 70% alcohol for one minute, rinsed in tap water, and stained in saline are reported as medians with interquartile ranges (IQR); the Wilcoxon ranked 0.5% toluidine blue stain (pH 0.5) for 10 minutes.
sign test was used to analyse changes within a treatment group, and the Mann-Whitney U test Differential cell counts for neutrophils, macrophages, lymphocytes, bronchial epi-was used to analyse changes between treatment groups. The distribution of categorical data was thelial cells, and eosinophils were performed on slides stained with May-Grü nwald-Giemsa. analysed using Fisher's exact test. Correlations between data were examined by least square The best slide from each subject at each saline challenge was selected and scanned on low linear regression analysis. Significance for all tests was accepted at the 95% level. Repeatpower (40×) for a region of at least 400 cells which were able to be counted continuously. ability of the maximal response plateau and the DRR to methacholine were analysed by the Cells were counted on high power (100×) across the whole width of the slide in a direction method of Peat et al, 14 and repeatability of cell counts was assessed with analysis of variance by perpendicular to the direction of smearing until a total of 400 cells had been reached. Mast cell calculation of the coefficient of reliability (R). 9 counts were performed on the slides stained with toluidine blue by the same procedure, except that a total of 1500 cells was counted.
Results  Cell counting was performed blind to the subjects' identities. Results for each cell type Of the 60 volunteers screened for the study, 33
had mildly elevated maximal response plateaux were expressed as a percentage of the total cells counted. Intraobserver repeatability of differ-to methacholine and were eligible to participate in the trial. Of these 33 subjects, one withdrew ential cell counts was assessed by recounting 10 slides selected at random. Interobserver because of illness and one because of noncompliance. The data obtained from one subrepeatability was assessed by a second reader counting the same 10 slides.
ject were not included in the analysis because of poor repeatability of baseline spirometric values. The baseline characteristics of the salbutamol and placebo subject groups are shown     To the remaining sputum sample an equal in table 1. All but four subjects were lifetime non-smokers, and none of the subjects had volume of 1% dithiotrietol was added. This was vortexed and placed in a shaking water smoked for 10 years prior to the study. None had current symptoms of asthma or any sigbath for 30 minutes. The sample was then centrifuged at 700 g for five minutes at 4°C nificant chronic illness. All but two subjects completed the six assessment visits of the trial. and the supernatant removed and stored at 20°C until eosinophil cationic protein (ECP) Data from these two subjects have been included in the analysis, however, as they assay using an RIA-ECP kit (Pharmacia).
completed the post-treatment high dose methacholine challenge. Twelve subjects (five salbutamol, seven placebo) reported symptoms of   Dose-response curves to methacholine and respiratory tract infections during the trial, but there was no consistent effect of these episodes hypertonic saline were constructed by plotting the percentage fall in FEV 1 from the control on any measurement. Seven subjects (four salgroup.bmj.com on June 15, 2017 -Published by http://thorax.bmj.com/ Downloaded from      butamol, three placebo) reported past treat-Treatment with salbutamol had no significant ment with anti-asthma or present treatment effect on the DRR to methacholine. Figure 2 with anti-rhinitis medication, but there was no shows the mean DRRs of the active and placebo consistent effect on any measurement.
groups at the four high dose methacholine Compliance with treatment was checked by challenges completed during the study. The weighing the canisters from the returned metered mean change in DRR before and after treatdose inhalers. The weight loss from the 28 can-ment was 0.79% fall/ mol (0.42 to 1.51) in the isters returned showed that 25 subjects took at salbutamol group and 0.66% fall/ mol (0.37 to least six inhalations per day, while three subjects 1.17) in the placebo group (p=0.65). The took only five inhalations per day. These three repeatability of the DRR to methacholine at subjects were all in the placebo group. Two the two pretreatment measurements was ±2.1 subjects who failed to return their canisters gave doubling doses (DD) for the entire group and a verbal assurance of compliance. Exclusion of did not differ significantly between the active the data from these five subjects did not alter group (±2.4 DD) and placebo group (±2.0 the results of any statistical analysis. DD). There was a significant correlation between the DRR to methacholine and the maximal response plateau (r=0.73, p<0.001).    There was no difference in mean baseline FEV 1 or FVC values at any assessment. The repeatability of the maximal response plateau was    ±7.2% for the entire group and did not differ Figure 3 shows the individual changes in maxsignificantly between active (±7.5%) and pla-imal percentage fall in FEV 1 to hypertonic cebo (±7.1%) groups. Treatment with sal-saline in the active and placebo groups. All butamol had no effect on the maximal response but two subjects had a plateau on their dose plateau to methacholine. Figure 1 shows mean response curve to saline. The treatment groups values for the maximal response plateau at differed significantly both in median change in screening, before and after treatment, and at maximum percentage fall in FEV 1 (salbutamol the follow up assessment. The mean change in 6.0% (IQR 11.0), placebo 1.3 (5.5)%, p= the maximal response plateau before and after 0.04) and change in DRR (salbutamol 0.45%/ treatment was a fall of 3.1% (−1.8 to 7.95) in ml (IQR 1.04), placebo 0.11 (0.29)%/ml, p= the salbutamol group and a fall of 0.6% (−3.61 0.03). In the active group the maximum perto 4.8) in the placebo group.
centage fall in FEV 1 increased from a median nificant difference between the groups in the ECP levels before and after treatment or the mean change in ECP after the treatment period (active −11.7 ng/ml (−45.1 to 21.8); placebo 0.32 ng/ml (−9.8 to 10.4); p=0.49). There (IQR) of 3.8% (11.0) before treatment to 10.7% (14.6) after treatment (p<0.01), and was a tendency for sputum levels of ECP to fall in the salbutamol group (30.4 ng/ml (95% the median DRR (IQR) increased from 0.24%/ ml (0.60) before treatment to 0.68%/ml (0.65) CI 0.7 to 60.0) before treatment, 19.9 ng/ml (1.1 to 38.5) after treatment), but this did not after treatment (p<0.01). In the control group there was no change in the maximum per-achieve statistical significance. There was no change in the sputum levels of ECP in the centage fall in FEV 1 with a median (IQR) of 1.7% (3.0) before treatment and 3.0% (4.0) control group (6.5 ng/ml (−3.1 to 16.3) before treatment, 6.9 ng/ml (4.0 to 9.7) after treatafter treatment (p=0.29), or in the DRR with a median (IQR) of 0.08% fall/ml (0.14) before ment). treatment and 0.19% fall/ml (0.15) after treatment (p=0.17).
Discussion This study has shown that salbutamol, inhaled regularly for four weeks, did not increase airway   Twenty two subjects (79%) were able to pro-sensitivity or maximal response plateau to methacholine in rhinitic non-asthmatic subjects duce sputum during both saline challenges, and 24 (85%) were able to produce sputum with mildly increased maximal response plateaux. Salbutamol use was associated with a during at least one saline challenge. Only the data from the 22 subjects (11 in each group) small but significant increase in airway responsiveness to hypertonic saline. There was who produced samples both before and after treatment were included in the analysis. For no detectable change in inflammatory cells present in induced sputum. the entire subject group the mean differential eosinophil count at baseline was 3.3% of total Previous studies 1-3 which have suggested that regular agonists cause an increase in airway cells counted (95% CI 0.5 to 6.0) and the mean mast cell count was 0.12% (95% CI 0.0 hyperresponsiveness have only examined asthmatic subjects, so it is not clear whether such to 0.3). There was no significant difference in mean cell counts of the active and placebo effects are peculiar to the asthmatic state. Nonasthmatic rhinitic subjects were recruited for groups either at baseline or after treatment (table 2). The mean change between the cell this study for several reasons. Firstly, we wished to exclude subjects who were taking regular counts before and after treatment did not differ significantly between groups for either eos-agonist medication to avoid any confounding effects of persistent receptor stimulation. Secinophils (active −3.74 (−9.8 to 2.5); placebo −3.0 (−6.3 to 0.2); p=0.83) or mast cells ondly, we wished to include subjects with a maximal response plateau to inhaled metha-(active 0.1 (−0.1 to 0.4); placebo −0.1 (−0.2 to 0.4); p=0.13). Exclusion of the non-atopic choline of more than 15% fall in FEV 1 . This criterion was based upon the results of an open subjects did not alter the results. Intraobserver and interobserver repeatability of cell counts trial, previously undertaken in our laboratory, which showed a significant increase in plateau was very good (coefficient of reliability >0.8) or good (coefficient of reliability 0.61-0.8) for after regular agonist use only in non-asthmatic subjects with a baseline plateau of more all cell types, except for the intraobserver counts of lymphocytes which were moderately re-than 15%. Many subjects with rhinitis have mild airway hyperresponsiveness, 15 and we expeatable (R=0.44).
There was no relationship at baseline or after pected that some of our patients would have an increased maximal response plateau; 55% treatment between differential sputum eosinophil or mast cell counts and the DRR or of screened subjects met the criterion of a maximal response plateau of more than 15%. In the maximal response plateau to methacholine, or the maximal percentage fall in FEV 1 or DRR asthmatic individuals it is not usually possible to measure a maximal response plateau during to hypertonic saline. The eosinophil and mast cell counts at baseline did not predict change methacholine challenge. 10 Thirdly, subjects with rhinitis are likely to be atopic. If agonists in DRR or maximal percentage fall in FEV 1 to hypertonic saline or methacholine after treat-alter airway sensitivity by increasing the extent of allergic inflammation of the airways, as has ment, and there was no relationship between individual changes in eosinophil or mast cell been proposed, 1 this change might be most group.bmj.com on June 15, 2017 -Published by http://thorax.bmj.com/ Downloaded from evident in atopic individuals. Of the 30 subjects changes in numbers of inflammatory cells in induced sputum or in ECP levels is consistent recruited in this study 29 had rhinitis and 27 were atopic.
with the view that regular agonist does not directly increase airway inflammation. At baseline the active group was slightly more responsive to methacholine and to hypertonic Two studies in asthmatic subjects have shown that regular salbutamol causes no saline than the control group, although this difference was not significant. Four subjects change in mast cell numbers 19 20 in bronchial biopsy specimens, which is in accord with our had responses to methacholine in the hyperresponsive range (DRR >5% fall in FEV 1 / mol finding in sputum of atopic non-asthmatic subjects. Manolitsas et al 20 also showed that, after methacholine) 16 and two of them experienced a fall in FEV 1 of more than 20% during the regular salbutamol, the change in the number of eosinophils in bronchial biopsy specimens hypertonic saline challenge. A response of this magnitude is usually seen only in asthmatic both in total numbers and in the number of activated cells did not differ from that after individuals, 8 although these subjects did not report symptoms of asthma and were not being placebo, nor was there any significant change in the concentration of ECP in bronchoalveolar treated for asthma. Despite double blind randomisation, two of the three non-atopic sub-lavage fluid.
An increase in mast cell activity is a possible jects (including the non-rhinitic subject) were assigned to the control group, and three of the explanation for the increased airway responsiveness to hypertonic saline, which is befour subjects with airway hyperresponsiveness (including the two subjects hyperresponsive to lieved to induce bronchoconstriction by stimulating mast cell degranulation. 8 2 rehypertonic saline) were assigned to the active group. Use of a crossover study design may ceptors are present on mast cells and exert a stabilising effect on these cells. 21 It has been have overcome this problem, but this approach was rejected because, at the time the study suggested that regular administration of a agonist may cause tachyphylaxis of receptors was planned, we were unable to determine the length of the washout period between treat-on mast cells, thereby reducing mast cell stabilisation. 5 6 Tachyphylaxis of the receptor ments required to reverse any effect of agonists. Exclusion of the data from the on human mast cells has not been proven; however, oral 22 and inhaled 23 agonist adhyperresponsive subjects did not substantially alter the results. ministration causes tachyphylaxis of the receptor on circulating human leucocytes and, Regular inhaled salbutamol was associated with a small but significant increase in sensi-in animal models, agonist-induced tachyphylaxis of receptors on airway mast cells has tivity and a maximal percentage fall in FEV 1 to hypertonic saline but had no effect on sensi-been demonstrated. 24 Recent studies of regular agonist use in asthmatic subjects have also tivity or the maximal response plateau to methacholine. While methacholine constricts suggested that increased mast cell activity, resulting from tachyphylaxis of the mast cell airway smooth muscle directly, hypertonic saline acts indirectly via release of mediators from receptor, is responsible for an increase in airway responsiveness. 6 Three studies have shown an airway inflammatory cells. The results of this study suggest that regular salbutamol affects increase in both the early and late asthmatic response to inhaled allergen following regular the indirect, but not the direct, component of airway responsiveness. However, regular salagonist use. 6 22 25 Another study reached a similar conclusion by comparing the bronchobutamol inhalation was not associated with a change in eosinophil numbers or ECP levels in protective effect of terbutaline to challenge with methacholine and with AMP (a mast cell the sputum, suggesting that eosinophils had no role in increasing responsiveness to hypertonic stimulus) after seven days of treatment with terbutaline. 5 If tachyphylaxis of receptors saline. An effect of agonists on ECP levels cannot be ruled out, however, since the wide modifies the release of mediators from mast cells, then the results of the present study, in confidence intervals suggest that the absence of significant changes may be a type II error. which both the sensitivity and the level of the plateau to hypertonic saline increased, suggest The number of mast cells did not increase but we have no index of mast cell activation.
that both the sensitivity of the mast cells to releasing stimuli and the total amount of meThere are several potential mechanisms by which regular use of agonist drugs could diators released may be affected. It may not be appropriate to extrapolate increase airway responsiveness, but most are not supported by the findings of the present this result directly from rhinitic non-asthmatic subjects to asthmatic subjects as the instudy. The absence of any effect on the response to methacholine suggests that tachyphylaxis of flammatory processes of the airways in these two groups may be different. However, anecairway smooth muscle receptors, which may reduce the ability of receptor stimulation to dotal evidence from two subjects suggested that the change in hypertonic saline reoppose bronchoconstriction, 17 is not a likely mechanism. Small increases in airway wall sponsiveness may be large in asthmatic individuals. Both these subjects had airway thickening, which could be induced after agonist use by vasodilatation of the airway hyperresponsiveness to methacholine at screening and experienced a reduction in FEV 1 of vasculature 18 or by an inflammatory cell infiltrate, might be expected to increase airway more than 20% at the pretreatment hypertonic saline challenge. Following treatment with salresponsiveness to direct stimuli, 7 and the absence of such changes suggests that this mech-butamol one of these subjects experienced a substantial increase in the maximal percentage anism is also unlikely. The absence of any group.bmj.com on June 15, 2017 -Published by http://thorax.bmj.com/ Downloaded from cell counts to investigate airway inflammation in asthma.
fall to hypertonic saline; the other subject 
